Independent portfolio analysisAudit period: October 20267,139 encounters · 30,286 line items

Are India’s Prescription Patterns Balancing Clinical Quality and Patient Affordability?

An interactive exploration of prescription quality, medicine affordability, patient safety, and pharmaceutical market access using the October 2026 audit report.

Explore the FindingsView the Methodology
1 · Affordability
93.02% branded
Reported potential saving ₹52.56 L/month
2 · Prescribing quality
4.22 drugs / encounter
vs reported WHO reference 1.6–1.8
3 · Patient safety
9.65% DDI screened
Allergy documented in 23.21%

RxAudit Intelligence is an independent analytical project built on a supplied report. It is not an official government, hospital or company platform, and the underlying data was not collected or validated by the author.

Executive KPI dashboard

Figures as reported in the source. Hover dotted terms for definitions.

The prescription affordability gap

Reported potential, not realised savings.

Branded spend (reported)
₹67.86 L /mo
Annualised: ₹8.14 Cr (×12, report)
Generic-alternative spend (derived)
₹15.30 L
= 67.86 − 52.56 (our calculation)
Reported potential saving
₹52.56 L /mo
77.44% · ₹6.31 Cr/yr (×12 verified)

Illustrative savings calculator

Monthly: · Annual: · % of reported spend

Formula: ₹67.86 L × eligible% × uptake% × price reduction%. Scenario inputs are illustrative assumptions, not observed data. Not every medicine can be safely substituted (e.g. clinical, bioavailability or availability constraints) and theoretical savings are unlikely to be fully realised.

Prescribing quality vs reference values

Reference type is shown for each row. A gap versus a reference is not by itself proof of inappropriate prescribing.

Interpretation. Medicines per encounter is the largest relative gap (+134% over the top of the reported 1.6–1.8 range, our check ✓). Generic-name prescribing (6.98%) and EML share (25.59%) sit far below the report’s 100% targets. Antibiotic and injection shares are modestly above the cited intervals. STG concordance (53.9%) has no stated benchmark in the report.

Healthcare-tier comparison

Observed aggregate differences only; geographic tier is not shown to cause them.

Equity note. Tier 4/Rural has the highest reported spend (₹1,033.70), medicines per encounter (4.49), polypharmacy (34.68%) and potential saving per encounter (₹798.18); Tier 1 is lowest on each. The report’s claims about income and “regulatory supervision” are not supported by data shown in it, so are not repeated here as findings.

Clinical governance & patient safety

Reported documentation indicators (% of prescriptions/encounters). Largest gaps highlighted.

Gaps: allergies not documented in 76.8%, DDI screening absent in 90.4%, route missing in 38.0% (all ✓ = 100 − reported). The report’s NABH score is 61.64% (reference: 85%; scoring method not provided).
The report lists 24 flagged disease–drug contraindication incidents, but its table is truncated in the supplied PDF (two rows partly visible), so they are not reproduced here.
Disclaimer: this site is for educational and analytical exploration and is not a substitute for professional clinical judgement.

Molecule & formulation intelligence

Frequency alone does not imply inappropriate use.

Pantoprazole prescriptions
1,347
Reported as 18.9% of encounters (1,347 ÷ 7,139 = 18.87% ✓, assumes ≤1 per encounter)
Top ingredients (rank order, chart values not labelled in source)Pantoprazole, paracetamol, metformin, telmisartan, aspirin, methylcobalamin + pyridoxine + vitamin D3, aceclofenac, rosuvastatin
Leading brands (by volume)Pantop, Let, Paracetamol, Ecosprin, Pan 40, Zerodol SP

Formulation mix (% of 30,286 line items)

Listed forms total 97.5%; the remainder is not described in the report.

Strategic recommendations

Proposed actions drawn from the report. Not completed interventions or proven outcomes.

Insight explorer

Methodology, sources & limitations

Source: National Clinical Prescription Audit & Pharmaceutical Market Access KPI Report, October 2026 (report generated 23 Oct 2026; PDF printed from prescription-audit-oct26.surge.sh). Aggregate figures only; no patient-level data was available. Benchmarks (WHO/DAP/93.1 indicators, NMC targets, NABH 85%) are as attributed in the report and were not independently verified.

Verified ✓ (our arithmetic): tier encounters sum to 7,139; tier-weighted spend = ₹67.86 L; tier savings sum to ₹52.56 L; savings = spend − generic alternative in each tier; 52.56 ÷ 67.86 = 77.45%; polypharmacy 2,311 ÷ 7,139 = 32.37%; financial-risk bands sum to 7,139; formulation shares match counts.

Inconsistencies to flag. (1) 30,286 ÷ 7,139 = 4.24 medicines/encounter, not the reported 4.22 (tier-weighted: 4.21). (2) The report’s tier saving percentages (52.02%, 70.01%, 68.71%, 69.28%) do not match its own figures: saving ÷ spend is about 77–78% in every tier. (3) “Avg monthly spend” and “savings” per encounter have no stated denominator or method for the generic price basis. (4) Audit period is October 2026 but the report was generated 23 Oct. (5) Sampling design, facility selection and “45+ hubs” are not described, so representativeness is unknown. (6) The report’s own labels (“official”, “violation”, “inverse care law”, “brand pushing”) assert causation or non-compliance without shown evidence; this site does not adopt them. (7) The 24 contraindication cases cannot be reviewed in the supplied PDF.

Limitations: no significance testing, causal inference or national representativeness is claimed. Savings are theoretical potential. Calculator scenarios are illustrative.